PUBLIC COMPANY
saveMayo Clinic
updated 2mo ago
Mayo Clinic is a private American academic medical center focused on integrated healthcare, education, and research. It maintains three major campuses in Rochester, Minnesota; Jacksonville, Florida; and Phoenix/Scottsdale, Arizona.
community read0 votes
🐶 often sniffed alongside
top 8- tagOncology7 co-mentions · 6 sources
- tagGlioblastoma4 co-mentions · 1 sources
- tagEndocrinology & Metabolism4 co-mentions · 4 sources
- tagImmunology3 co-mentions · 3 sources
- tagPain2 co-mentions · 2 sources
- tagHematology1 co-mentions · 1 sources
- tagNephrology1 co-mentions · 1 sources
- tagCardiology1 co-mentions · 1 sources
pipeline
1
marketed
0
phase 3
0
catalysts ytd
19
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- N/AAdverse Outcomes and Mortality in Liver Transplant
- phase4Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
- N/AA Study of Virtual Reality and Linaclotide for IBS-C
- phase4A Study of a Novel Precision Medicine Approach For Obesity
- —Collecting Blood and Stool Samples to Detect Colorectal Cancer or Advanced Neoplasia in Lynch Syndrome Patients
- N/APilot Evaluation of the StarGuide Next Generation SPECT/CT System
- phase2Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
- N/AProspective Use of Philips iSuite for Interventional Procedures
🐶 Hiring Signal
News
- Opinion: How to disrupt the health misinformation business modelOne way to fight medical misinformation: make it easier for people to understand when they are being manipulated, write Paul Martin Jensen and Avi Tuschman.stat · 3d ago
- Replimune’s twice-rejected melanoma drug prevails in FDA adcommFollowing a pair of FDA rejections of its melanoma drug, Replimune’s fortunes flipped today after an advisory committee voted 10 to 3 in favor of the candidate’s effectiveness.fiercebiotech · 17d ago
- STAT+: The whistleblower, The Lab, and the fine printIn this AI Prognosis news roundup: Mayo's AI whistleblower, Sutter Health's reply to lawsuit over Abridge scribe, and more.stat · 1mo ago
- Kardigan extends biotech’s streak of big IPOs with $400M haulIncluding the heart drug developer’s offering, four biotechs in 2026 have raised at least $400 million in IPO proceeds — the most in a single year since 2021, according to BioPharma Dive data.biopharma_dive · 1mo ago
- How AI helped treat a newborn’s ultra rare disease. ‘It was almost like a light switch.’The parents of Jorie Kraus told the audience at STAT's Breakthrough Summit West about how AI helped their daughter who was born with a rare disease.stat · 2mo ago
- Opinion: Hospitals are silencing doctors online, and it’s fueling the health misinformation crisisHospitals and health systems need to loosen the reins and let physicians combat social media misinformation, writes Adam Goodcoff.stat · 3mo ago
- Opinion: STAT readers on MAHA activists, perimenopause, and diversity in medical school“Unfortunately, the resources don't exist to take every flat-earther to the International Space Station to change their mind,” a STAT reader writes.stat · 3mo ago
- Trump drops Casey Means as surgeon general nominee, opts for radiologist Nicole SaphierTrump slammed Sen. Bill Cassidy for blocking his surgeon general pick, as he nominated a replacement.stat · 3mo ago
comments(0)
5-min edit window · permanent after that